Weather

89°F8:19 PM

Health

1 read

Essential Updates: Measles Risks, Youth Screen Time, and More

KVIA•Thursday, January 15, 2026 at 10:19 PM•CNN Newsource

Medical stethoscope representing healthcare news

Want the full story?

Read the complete article at KVIA

AI Summary

Recent reports indicate that measles cases in the U.S. have surged to a record high in 2025, raising concerns about potential exposure and the necessary precautions to take. Additionally, YouTube has introduced new parental controls allowing limits on screen time for teens, which ranges from two hours to complete blocking. In the realm of journalism, the Justice Department's recent actions have sparked fears of increased confrontations between press and authorities. Lastly, a Michelin-rated restaurant has come under scrutiny due to hygiene issues, contrasting its previous acclaim. These developments highlight ongoing public health concerns and the evolving landscape of media and technology.

Key Details: • Measles cases in the U.S. reached record levels in 2025. • YouTube now allows parents to limit teen screen time from two hours to zero. • Justice Department's search warrant for a reporter's home raises alarm in journalism. • A Michelin-starred restaurant faces criticism for hygiene after a negative report.

technology journalism measles youth hygiene

Related Articles

Novo Nordisk Cuts Prices of Ozempic and Wegovy by 50% Starting 2027

Novo Nordisk has announced a significant reduction in the list prices of its popular diabetes and weight loss medications, Ozempic, Wegovy, and Rybelsus, by up to 50% starting in 2027. The current list price for Wegovy is $1,349, while Ozempic and Rybelsus are priced at $1,028. This price cut aims to improve accessibility for patients, particularly those with high deductibles or co-insurance plans. The move comes as Novo Nordisk competes with Eli Lilly, which has gained market share in the obesity medication sector. Despite the list price reductions, self-pay prices will remain unaffected. The company recently reported disappointing trial results for its next-generation obesity drug, contributing to a decline in its stock price.

Trump's Glyphosate Order Sparks Controversy Among Health Advocates in El Paso

An executive order by President Trump has declared glyphosate, a widely used herbicide, essential for national security and economic stability, which has drawn ire from health advocates, particularly those associated with the 'Make America Healthy Again' (MAHA) movement. The order emphasizes the need for a domestic supply of glyphosate, despite ongoing health concerns about its potential carcinogenic effects. Critics, including Zen Honeycutt of Moms Across America, argue that this move may protect Monsanto from lawsuits related to glyphosate's health risks. The order coincides with Bayer's proposed $7.25 billion settlement over cancer claims linked to Roundup, the product containing glyphosate. Health experts warn of the herbicide's risks, especially to children, as studies indicate increased cancer risks associated with exposure.

How Technology is Enhancing Patient Engagement in Healthcare

Recent advancements in technology are significantly improving the way patients interact with their healthcare providers. Tools like home blood pressure monitors, glucometers, and smartwatches allow patients to collect vital health data, which can be shared during appointments to enhance treatment plans. For example, accurate blood pressure readings require validated devices and specific techniques to ensure reliability. This shift towards patient-generated data is transforming healthcare from a reactive to a proactive model, enabling more personalized care. However, while technology plays a crucial role, it is essential to maintain the personal connection during in-person visits.

El Paso Matters•Feb 23

El Paso Researchers Investigate Natural Remedies for Cancer and Heart Disease

Researchers at Texas Tech Health El Paso are exploring innovative treatments for pancreatic cancer and heart disease, targeting health issues prevalent in the community. Dr. Ramadevi Subramani Reddy is studying gedunin, a compound from the neem tree, with a $45,000 grant aimed at reducing the toxic side effects of chemotherapy. Pancreatic cancer affects El Pasoans at a rate of 8.8 per 100,000, highlighting the urgency for new therapies. Meanwhile, Dr. Kazue Okajima is analyzing blood thinners to improve survival rates for heart disease patients, supported by a $36,000 grant. The Lizanell and Colbert Coldwell Foundation has significantly contributed to these research efforts, totaling over $1.6 million since 1991.